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Marta Heise 1 , Piotr JarzeMski 2 , aneta Bąk 1 , anna Junkiert-CzarneCka 1 (3/103) andnotdetectedinanyhealthyman.Twomutationcarriersoriginatedfromtwo of25familiesfulfillinghereditaryprostatecancercriteria(HPC)andonemutation carrier from one family among 78 families without HPC (PC frequency: 8%vs.1.3%,OR=6.70,p=0.13).Intwoofthreemutationcarriers,disease was detected above 60 years of age. There was a trend for a lower probability of5-yearsurvivalinpatientswithG84Ethaninpatientswithoutit(66.7%vs. 94.0%,p=0.08). The HOXB13 G84E germline mutation is associated with increased prostate cancerriskinPolishmen,withhereditaryformofthedisease,andprobablywith olderageatPConset(>60yearsofage)andshortersurvival.However,itisnot associatedwithPSAlevel,orPCstageorgradeatthetimeofdiagnosis.
Introduction
Prostate cancer (PC) is a serious problem endangering men's health and life. Among all cancers in menitisthemostcommontypeindevelopedcountries. In Poland, prostate cancer is the second most common cancer type, after lung cancer [1, 2, 3, 4] . Positive family history of PC remains among the strongest known risk factors for the disease development. The genetic basis of prostate cancer is very complex. Through linkage analysis, numerous prostate cancer chromosomal loci have been identified, includingHPC1(1q25-25),PCaP(1q42-43),HPCX (Xq27-28), CAPB (1p36), HPC20 (20q13), 17p12, and 8p22-23. Three candidate susceptibility genes have been positionally cloned, RNASEL in HPC1, HPC2/ELAC2 in 17p12, and MSR1 in the 8p22-23 region, but none of these is a high-risk prostate cancer susceptibility gene [5, 6, 7, 8, 9, 10, 11] . Literature analysis indicates that mutations of genes that play important role in cellular cycle regulation and DNA repair mechanisms are associated with higherriskofPC.TheBRCA1,BRCA2, CHEK2,and NBS1belongtothesegroupsofgenes,buttheircon-tribution to prostate cancer aetiology is of relatively low importance [12 13, 14, 15, 16] . More than 70 commonlowpenetrancevariantsthatincreasePCrisk have been identified to date through Genome Wide AssociationStudies(GWAS) [17, 18, 19] .
In 2012 Ewing et al. described for the first time the relationship between G84E (c.251G>A, p.Gly84Glu) germline mutation of the HOXB13 gene and increased prostate cancer risk. In that investigation the researchers sequenced 202 genes in aprostatecancerlinkageregionat17q21.32among 94probandsfromprostatecancerfamiliesandthey found this rare recurrent mutation in four families. The G84E was found in 1.4% of cases and in only 0.1%ofcontrolsubjects(OR=20.1;p<0.0001) [20] . The G84E is located in the first exon of the genecausingthealterationfromglycinetoglutamic acid, which is predicted to affect protein function. ThenormalhomeoboxproteinHOXB13isinvolved in embryonic development of different organs and regulates transcription of androgen receptor (AR) target genes that are known to play a role in prostatecancergrowth[2122, 23, 24, 25] .Theresults obtainedbyEwinget al.wereconfirmedbyotherresearchersindifferentscientificcentres,andalsoindicated that G84E mutation was strongly associated with prostate cancer pathogenesis [19, 26, 27, 28, 29] .In2012Breyeret al.indicateda7.9-foldhigher riskofprostatecancerinG84Ecarriersthanthepopulationrisk [26] .Thecarrierratewas1.9%among all familial case probands, 2.7% among probands of pedigrees with at least three affected, and 1.5% among probands with no additional family history ofprostatecancer.In2013,Stott-Milleret al.reported results from a population-based, case-control study ofmeninwesternWashingtonState,wheretheyob-servedtheG84Emutationin1.3%ofpatientsversus 0.4%ofcontrols,whichreflectsa3.3-foldhigherrisk ofPCinG84Ecarriersversusnon-carriers [28] .Also in2013,Kluźniaket al.analysingaPolishpopulation indicated at five-fold higher risk of PC in patients withG84Ethanthepopulationrisk [27] .Mutation wasfoundin20/3515(0.6%)PCmenandin3/2604 (0.1%)menfromthegeneralPolishpopulation.Furthermore,G84Ewasfoundin4/416(1%)mencoming from HPC families, which was associated with a8.4-foldhigherriskofthiscancercomparedtothe general population. In 2014, Karlsson et al. exam-ined5003casesand4693controlsfromSwedenand showedthattheG84Emutationwaspresentin4.6% ofpatientsandin1.3%ofcontrols,provingastrong associationofthismutationwithPCrisk(OR=3.4) [29] .Interestingly,theG84Emutationhasnotbeen found among PC patients of Asian ancestry, who instead show other HOXB13 mutations evidencing allelicheterogeneityindifferentethnicbackgrounds [30] .
To establish whether or not the HOXB13 G84E mutation contributes to prostate cancer in Poland, andtomeasuretheimpactofthismutationoncancer risk, and on the clinical characteristics of prostate cancer, including survival time, we genotyped 103prostatecancermenand103controls.
Material and methods
ThematerialofinvestigationswerearchivalDNA samples stored in the Department of Clinical Ge-neticsCMUMKinBydgoszczfrom2005to2007. DNAwasisolatedfromperipheralbloodof103consecutive, newly diagnosed patients from all over Poland, regardless of age at prostate cancer onset, familyhistory,andhistologicaltypeofcancer.They were hospitalised because of prostate cancer at the DepartmentofUrologyoftheJanBizielUniversity HospitalinBydgoszcz.Theageatprostatecancerdiagnosis ranged from 45 to 75 years (the mean age 59.9±5.9years).Afamilyhistorywastakeneither bytheconstructionofafamilytreeorthecompletion ofastandardisedquestionnaire.Allfirst-andseconddegreerelativesdiagnosedwithprostatecancerand theageofdiagnosiswererecorded.Theestimationof patientfamiliesasthosewithahistorysuggestinghereditaryriskofprostatecancer(HPC)wasperformed on the basis of criteria defined by Carter et al. [31] andCybulskiet al. [11] .Among103prostatecancer patients, 25 (24.27%) originated from families sus-pectedofhavingHereditaryProstateCancer.
InformationaboutthePSAlevelbeforetheoperation was recorded for 97 patients, about the grade of prostate cancer cells for 101 patients, and about tumourstagefor102patients.
Dataonsurvivalwereavailablefor103PCpatients.
In 57 of 103 (55.34%) families, an aggregation ofcancersofthebreast,stomach,colon,ovary,lung, larynx,bladder,kidney,ormelanomaoccurred,inadditiontoprostatecancer.
ThecontrolgroupconsistedofDNAsamplesiso-latedfromperipheralbloodof103men-volunteers, healthyatthetimeoftheinvestigations.Theageof menrangedfrom46to74years(themeanagewas 59.9±6.6years;theageofcontrolswasmatchedto thePCgroup).
The study protocol was approved by the Ethics CommitteeoftheCollegiumMedicumNicolausCo-pernicusUniversityinBydgoszcz,Poland.EveryPC patientorcontrolgavehiswritten,informedconsent fortheuseofDNAsamplesforgenetictesting.
Analysis of G84E mutation
GenomicDNAwasextractedfrom5-10mlofperipheralbloodbythestandardsalting-outmethod.The G84EmutationwasgenotypedusingSangersequencing.Theprimersforamplificationofthecodingregion of the first exon were designed using Primer3 software(http://frodo.wi.mit.edu/).Theprimersequences were: 5'-CTTGGATGGAGCCAAGGATA -3' (HOXB13 Forward) and 5'-CCTCACCAGCTC-CAAGTCTC-3'(HOXB13Reverse).Theamplified DNA amplicon was sequenced using BigDye terminator v3.1 Cycle Sequencing Kit (Life Technologies), according to the manufacturer's protocol. Sequencing products were analysed on an ABI prism 3130 Genetic Analyzer (Applied Biosystems, Life Technologies). All sequences were compared with the HOXB13 RefSeq sequence (NG_033789.1) for mutationdetection.Sequencinganalysisofthefragment of HOXB13 first exon was performed in all menfromstudyandcontrolgroups. 
Statistical analysis

Results
Inourstudy,theG84Emutationwasdetectedin 3/103(2.9%)PCmen(heterozygouscarriers)butnot in any healthy man. The difference in frequency of G84E mutation between these two groups was not statistically significant (p = 0.19, trend) but with ahighoddsratio(OR=7.21).
Patients positive for G84E mutation were more likelytohaveafamilyhistoryofprostatecancer(2/3) than those who were negative (23/100) (66.7% vs. 23%),butthisdifferencewasnotstatisticallysignificant (p = 0.26). The pedigrees of the three G84E mutation carriers are shown below (Fig. 1 ). In the firstHPCfamily,PCwasdiagnosedinaprobandat 51yearsofageandinhisfatherat68yearsofage. Additionally,stomachcancerandbraintumourwere diagnosed in two of the second-degree relatives of theproband.InthesecondHPCfamily,PCwasdiagnosedinthreerelatives,inaprobandat67years of age and in his two uncles (mother's brothers) at unknownage.Inthisfamily,stomachcancerwasdiagnosed in the proband's father at 60 years of age. Inthethirdfamily,whichdidnotmeettheHPCcri-teria,PCwasdiagnosedintheprobandat61yearsof ageandtestiscancerinhissonat31yearsofage.In allthreefamiliestheG84Emutationwasnottested inprobands'relatives.
TheG84Ecarrierswerenotmorelikelytobediagnosed with prostate cancer in younger age than non-carriers. The mean age of PC diagnosis was 59.7 ±8.01 years for mutation carriers versus 60.0 ±6.0 years for non-carriers; this difference was not statistically significant (p = 0.93). G84E was detectedintwoofthreemutationcarriersatmorethan 60yearsofageandinoneatlessthan60years.
The clinical characteristics of prostate cancer in G84Ecarriersandnon-carriersarepresentedinTable I. No statistically significant differences in the presence of PSA concentration >20 ng/ml, highgrade Gleason Score (GS ≥ 8), or advanced TNM stage (T3/4), depending on carrier status, were observed. There were no statistically significant differences between mean serum PSA level in G84E carriers and non-carriers (10.4 vs. 8.1, respectively; p=0.12).
Dataonsurvivalwereavailableforall103investigatedmen.Therewasonedeathrecordedamongthree G84E carriers and seven deaths among 100 G84E non-carriers. The probability of 5-year survival for thecarrierswas66.7%,comparedto94.0%fornoncarriers(p=0.08).Figure2showstheKaplan-Meier curvesforG84Ecarriersandnon-carriers.
Discussion
Theresultsofourstudyconfirmtherecurrentna-tureofHOXB13 G84EgermlinemutationinPolish prostatecancerpatients.G84Emutationoccurredin threemeninthestudygroup(2.9%)butinnobodyin thecontrolgroup.Kluźniaket al.,studyingaPolish population, also found a higher incidence of G84E mutationinmenwithPC(0.6%)thanintheircontrol group (0.1%). The difference in the prevalence of this mutation in both groups might result from thedifferentsizesofthesegroups(103and2604persons) [27] .Karlssonet al.showedahigherincidence ofG84EinagroupofPCmenfromSwedenthanin anationalcontrolpopulationcollectedbetween2001 and2003(4.6%vs.1.4%),orinagroupofPCmen coming only from Stockholm (biopsy-positive patients)thaninbiopsy-negativecontrolscollectedbe-tween2005and2007(4.3%vs.1.3%) [29] .Inthis study,theoddsratio(OR)ofPCoccurrenceinG84E carrierswasestimatedat7.21(similarly,intheBreyeret al.study [21, 26, 29, 32] .InthestudybyKote-Jaraiet al.theORofaPC occurrence in G84E carriers was slightly lower and wasestimatedat2.93(intheChenet al.study-3.8) [19, 33] . Except in the Chinese population, where the G84E was not present, all the studies carried thusfarhaveconfirmedthesignificantroleofG84E mutation in prostate cancer development [20, 21, 26, 27, 29, 30] .
Breyeret al.revealeda1.9%G84Efrequencyin menfromfamilieswithatleastonecaseofprostate cancer,2.7%inmenfromfamilieswithatleastthree PCcases,and1.5%inmenfromfamiliesinwhichno PCcasewasdetected [26] .Kote-Jaraiet al.reported theprostatecancerriskbeingsignificantlyhigherfor HOXB13 G84Emutationcarrierswithafamilyhistory of PC (defined as prostate cancer in a first-or second-degree relative at any age) compared with non-carriers, with an OR of 4.7. The frequency of G84Emutationinprostatecancerpatientswithfam-ilyhistoryofPCwas2.4%andinthosewithnofamilyhistory(definedaslackofPCinafirst-orseconddegreerelative)wastwo-timeslower,at1.2% [19] . In our study, the G84E frequency in patients from families with HPC (8.0%) was significantly higher than in patients from families which did not fulfil the HPC criteria (1.3%). The association of G84E withthehereditaryformofPCwasalsoconfirmedby Kluźniaket al.andEwinget al. [20, 27] .
AnanalysisoftheageatPConsetofG84Ecarriers in our study shows that the presence of this muta-tionmaybeassociatedwitholderageatPConset;in 2of3G84Ecarriers,prostatecancerwasdiagnosed atage>60years(61and67years [20] .Thus,furtheranalysisoftheage [27] .Inthestudy by Kote-Jarai et al., HOXB13 G84E presence also wasnotrelatedtooverallsurvival [19] .Inourstudy, althoughthestudygroupconsistedofonlythreecarriers, a tendency for shorter survival of PC patients withG84Emutationthanpatientswithoutthismutation could be observed (p = 0.08). Two of three (66%)mutationcarriersand93%ofmutationnoncarriers survived for five years after prostate cancer diagnosis.
Inourstudy,nostatisticallysignificantdifferences innegativeprognosticfactors,suchasPSAconcentra-tion>20ng/ml,high-gradeGleasonScore(GS≥8), oradvancedTNMstagetumours(T3/4),depending oncarrierstatus,wereobserved.InthestudybyKote-Jaraiet al.therewasnoassociationbetweenGleason Score, prostate-specific antigen level, or tumournode-metastasis(TNM)stage,andG84Ecarrierstatus [19] .However,Storebjerget al.,studyingaDanishpopulation,showedthatHOXB13G84Ecarriers weresignificantlymorelikelytohaveahighermean PSAlevelandpathologicalGleasonscore≥7atthe time at PC diagnosis than non-carriers (respectively, 19.9vs.13.6,p=0.03and83.3vs.60.9,p=0.03). The authors indicated that G84E mutation carriers weremorelikelytodevelopaggressivePCcompared tonon-carriers [32] .
Conclusions
The results of our study confirm the results obtained by other researchers that HOXB13 G84E mutationisassociatedwithincreasedprostatecancer risk. Carriers of this rare mutation are more likely tohaveafamilyhistoryofprostatecancercompared withhomozygotesforthewild-typeallele.Additionally,G84Emutationpresencemaybeassociatedwith olderageatPConset(>60yearsofage)andwith shorter survival of mutation carriers. No significant differencesinmutationfrequencyweredetectedaccordingtoselectedclinicalcharacteristicsofprostate cancerpatients.
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